Conjugated Estrogens + MPA: The Definitive Guide

What are Prempro and Premphase?

Prempro combines conjugated estrogens, or CEE, with medroxyprogesterone acetate, or MPA, in an oral tablet for specified menopausal indications in women with a uterus. CEE is a mixture of estrogens obtained from pregnant mares’ urine. MPA is a synthetic progestin that opposes estrogen stimulation of the uterine lining; it is different from micronized progesterone. [1]

Premphase uses the same hormone classes in a sequential pack: estrogen-only tablets followed by combined tablets. That is a different calendar, not a lower-strength Prempro or a hormone-free contraceptive week. The complete regimen, including its progestin days, is the treatment being prescribed. Neither product is a contraceptive schedule. [1]

These selected US labels remain revised April 2025 in the manufacturer text retrieved. They should not be described as automatically rewritten by the FDA’s first-six February 2026 announcement. The guide verifies named documents, not worldwide stock, insurance coverage or Canadian authorization. [1], [4]

How do the continuous and sequential schedules differ?

The listed strengths are complete pairs. The label instructs the lowest effective dose for the individual, not a universal start at the WHI dose or an automatic progression through all strengths. Matching only the CEE amount would miss a change in MPA exposure. A higher tablet is not necessarily the solution to bleeding, mood symptoms or missed medication. [1], [3]

In Premphase, the first half is not inert: it contains CEE. The second half contains CEE and MPA. Follow the actual pack sequence and arrange a specific transition before changing from another regimen. Calendar tracking should name both the tablet and phase rather than record every day simply as estrogen. [1]

Evidence note: full named US label. Neither separate component dosing nor a patch-equivalence conversion is inferred.

Which symptom and bone goals fit the indications?

Hot flashes and night sweats are systemic treatment goals. Better sleep when sweats ease can be useful, but the regimen does not become a treatment for every cause of depression, tiredness or poor concentration. Decide which symptom should improve, what functional change matters and when the clinician will reassess it. [1], [3]

The US label also includes moderate-to-severe vulvar/vaginal atrophy. If those are the only symptoms, consider a topical vaginal treatment. Its osteoporosis-prevention indication is limited to significant risk after careful consideration of non-estrogen medicines. Prevention, treating established osteoporosis and treating disruptive hot flashes are different decisions, even if one regimen affects more than one outcome. [1]

How do oral delivery and missed tablets matter?

These tablets are swallowed, with oral first-pass liver exposure. A change to transdermal estradiol changes formulation and route; it requires a separate adequate progestogen plan with a uterus. Do not equate CEE mixture milligrams with estradiol milligrams or use the word natural to promise lower risk. [1], [3]

The patient leaflet says take a missed dose promptly unless the next is almost due; then skip it, without taking two doses together. For Premphase, tell the clinician or pharmacist which phase and tablet were missed when advice is needed. A remembered tablet is not permission to redesign the remaining progestin phase. [1]

How should the WHI evidence be interpreted?

WHI directly studied daily oral CEE 0.625 mg plus MPA 2.5 mg against placebo in its combined trial. Participants were 50–79 years old, with mean age around 63. This is more directly relevant to that named Prempro pair than to an unrelated estradiol product, but a study population still is not an individualized forecast. Starting age, time since menopause, baseline risk, duration and treatment purpose matter. [1], [2]

The combined trial found important vascular and breast-cancer harms alongside benefits such as fracture reduction. The estrogen-alone trial enrolled women after hysterectomy and is a different population; its results cannot remove MPA-associated considerations in a woman with a uterus. WHIMS dementia findings in older participants should not be called proof of the same outcome in all younger users. [1], [2]

Lower Prempro strengths and sequential Premphase were not the exact combined WHI intervention. Their label retains class precautions without establishing identical numerical event rates. Conversely, absence of the same trial does not prove no risk. Modern symptom-treatment decisions use the relevant evidence and clinical context, rather than treating WHI as either irrelevant or a universal yes/no answer. No cardiovascular or dementia-prevention indication is supplied. [1], [2], [3]

What safety issues should be reviewed first?

Unexplained genital bleeding, breast or estrogen-dependent cancer, current/past venous clots or arterial thromboembolic disease, relevant thrombophilia, liver disease and serious allergy can make the regimen unsuitable under the label. Included MPA reduces unopposed endometrial stimulation but does not cancel breast, clot or vascular risks. Sudden chest pain, breathlessness, a swollen painful leg, weakness or speech trouble requires urgent assessment. [1]

Breast pain, headache, nausea, abdominal symptoms, swelling and mood concerns can affect tolerability. Keep the timing and impact clear without assuming that one component caused every symptom. Medicine review includes CYP3A4 inducers/inhibitors and aminoglutethimide, which can reduce MPA exposure. Thyroid-replacement users may need thyroid-function monitoring. New significant symptoms or pregnancy concerns deserve individual assessment, not automatic escalation. [1]

What should the review record?

Record product, both amounts, continuous or sequential days, missed tablets, hot flashes, sleep, bleeding and adverse effects. Distinguish a planned sequential withdrawal bleed from unexpected continuous-regimen bleeding. The label encourages periodic reassessment; its patient example is every three to six months. NICE recommends review at three months and annually thereafter, earlier for difficulties. These are review frameworks, not conflicting universal lab calendars. [1], [3]

NICE calls for prompt assessment of persistent unscheduled systemic-HRT bleeding beyond six months after starting or three months after a change; concerning bleeding can need earlier review. Screening, imaging or laboratory tests should answer a clinical question. A normal estradiol number is not proof of correct phase use or a reason to dismiss bleeding. [1], [3]

How should stopping or a new calendar be planned?

Stopping a fixed tablet changes both hormones; stopping a sequential pack also changes the planned phase exposure. NICE permits gradual reduction or immediate stopping. Set the reason, likely symptom recurrence, new regimen if any and follow-up date before improvising skipped days or replacing tablets. Serious suspected adverse reactions need prompt assessment. [1], [3]

If estrogen continues separately, include adequate endometrial protection with a uterus from the start of the new plan. If systemic treatment ends, a local vaginal treatment can be a separate ongoing decision. A wish to stop MPA does not establish that estrogen alone is suitable or that a skin progesterone cream provides equivalent protection. [1], [3]

What does the named label say about storage?

Store at 20–25°C, with excursions permitted to 15–30°C. Keep the pack sequence, expiry and medicine identity available; for Premphase, preserving phase information is as important as knowing the brand name. Ask a pharmacist about damaged packaging, heat exposure or tablets removed from an uncertain pack. Do not borrow storage from a cream or discard instructions from another country product. [1]

How do other uterine-protection options differ?

Separate estradiol and progestogen allow different routes or independent adjustment, at the cost of a more complex plan. Bijuva is another oral combination with different molecules and its own food instructions. Duavee uses bazedoxifene rather than MPA; its no-additional-hormone rules are different. No head-to-head all-outcome winner follows from the names synthetic or bioidentical. [1], [3] [6], [7]

Compare complete indication, route, components, bleeding pattern, contraindications and reliability of use. Concern about an MPA effect is a reason to discuss an alternative protection plan, not to keep CEE and silently omit protection. The option chosen should still address the symptom or bone goal that justified treatment. [1], [3]

What themes appear in public Prempro accounts?

Freshly retrieved reviews describe perceived hot-flash/night-sweat relief, improved sleep and daily function, along with breast discomfort, other unwanted effects, cost concerns and different decisions about continuing. Those whole-regimen accounts do not isolate MPA or certify efficacy for every symptom mentioned. Reports about neurologic or psychiatric illness are not evidence to stop unrelated treatment. [5]

No rating, identity, direct quote, submitted amount or response timeline is reproduced. An older price or assistance story does not verify today’s coverage. Public experience can help phrase questions about benefit and practical access; it does not replace randomized evidence or measure cancer and clot incidence. [1], [2], [5]

Common questions about Prempro and Premphase

Does Premphase include a week without estrogen?

No. Its named cycle gives CEE on all 28 days and MPA in the second half. The estrogen-only tablets are not inert. [1] The first phase is active estrogen treatment and the later phase adds the named progestin. That differs from a contraceptive pack’s inert interval and from taking both components daily in Prempro. Keep the actual package and day sequence visible, especially when a replacement is proposed. See the calendar comparison. [1]

Is the WHI dose every person’s starting dose?

No. WHI studied 0.625 mg CEE/2.5 mg MPA; the label lists other pairs and individualized lowest-effective dosing. [1], [2] The studied combined WHI intervention should remain attached to its population and comparator. A different listed strength or sequential regimen does not inherit a precise WHI event forecast, but it also is not thereby proved risk-free. Ask which evidence applies to the proposed treatment. See WHI interpretation. [1], [2]

Does MPA eliminate uterine cancer risk?

No. It reduces unopposed stimulation under the complete regimen; abnormal bleeding still needs assessment. [1], [3] The protection evidence belongs to the amount and schedule of the complete regimen, not an unlimited ability to offset added estrogen. Report new or persistent bleeding with timing, missed tablets and changes. Assessment should consider the symptom rather than only whether a progestin is present. See monitoring and bleeding. [1], [3]

Does the first-six FDA announcement mean Prempro has no warning?

No. The retrieved full manufacturer text is April 2025 and the announcement names other products. Current package and later changes need checking. [1], [4] Changing or removing boxed language for other named products does not revise this retained full label or settle individual suitability. Contraindications, ordinary warnings and the actual combined regimen remain relevant. Ask about the latest information supplied with the medicine instead of relying only on a class headline. See risks and label scope. [1], [4]

Can I use Prempro and Premphase as the same calendar?

No. Prempro is a continuous fixed combination, whereas Premphase changes the progestin exposure within its named cycle while maintaining estrogen. Their calendars should not be exchanged merely because both contain CEE and MPA. If the treatment changes, ask for the actual new pack, component amounts, day sequence and review plan. The protocol table shows the distinction; it does not select the appropriate regimen for you. [1]

Glossary

Definitions for interpreting the product, calendar and limitations.

Estrogen

A hormone class that includes estradiol, estrone and estriol.

MHT / HRT

Menopausal hormone therapy; hormone replacement therapy is a broader term.

Vasomotor symptoms

Menopausal hot flashes and night sweats.

GSM

Genitourinary syndrome of menopause: symptoms and tissue changes involving genital and urinary areas.

Systemic treatment

Medicine delivered through the circulation to act throughout the body.

Local treatment

Treatment directed mainly at the tissue where it is applied; some absorption can still occur.

First-pass metabolism

Initial liver processing after a swallowed medicine is absorbed from the gut.

Endometrium

The lining inside the uterus.

Endometrial hyperplasia

Excess growth of uterine lining; some forms can precede cancer.

Progestogen

A medicine class including progesterone and synthetic progestins, used for uterine protection in systemic HRT.

Micronized progesterone

Progesterone processed into small particles to support absorption; route and schedule remain important.

Continuous combined

Estrogen and progestogen taken without planned monthly breaks.

Sequential

Progestogen taken during a defined part of an estrogen-treatment cycle.

Withdrawal bleed

A planned bleed associated with stopping the progestogen part of a sequential regimen.

Hysterectomy

Surgery to remove the uterus; it does not always remove the ovaries.

VTE

Venous thromboembolism: a clot in a vein, including leg clots and pulmonary embolism.

Pulmonary embolism

A clot blocking an artery in the lungs; a medical emergency.

Absolute risk

How often an event occurs in a specified population over a specified time.

Relative risk

An event rate in one group compared with another; it needs baseline risk to show practical size.

Contraindication

A circumstance in which a medicine should not be used according to its label.

Compounded product

A pharmacy-prepared medicine; approval of an ingredient does not approve the finished preparation.

Conjugated estrogens / CEE

An estrogen mixture, not a single estradiol molecule.

MPA

Medroxyprogesterone acetate, a synthetic progestin.

Fixed combination

Two active components in one dosage form, changed together.

How was this guide researched?

Named full labels define calendars, indications and risks. Marketing records do not prove stock; guidelines inform care without changing authorization. Public accounts remain separate from clinical evidence. Sources identify document revision and access.

How this page was made

This Doserly editorial guide was prepared with AI assistance using public sources checked October 2, 2026. No independent clinician reviewer is claimed. Doserly develops a commercial tracking app. Original figures explain concepts and do not represent trial results. The directory identifies source revisions and access limitations. January 2027 is a review target; new evidence can require an earlier check.

Sources and updates

Related guides